EBITDA Margin % is calculated as EBITDA divided by its Revenue. Oncopeptides AB's EBITDA for the
three
months ended in Mar. 2026 was €-3.48 Mil. Oncopeptides AB's Revenue for the
three
months ended in Mar. 2026 was €2.36 Mil. Therefore, Oncopeptides AB's EBITDA margin for the quarter that ended in Mar. 2026 was -147.82%.
Oncopeptides AB (FRA:OND) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Oncopeptides AB EBITDA Margin % Related Terms
Oncopeptides AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OND vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Oncopeptides AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (FRA:OND) has a EBITDA Margin % of -147.82% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #602 out of 944 companies in the Biotechnology industry, placing it in the top 63.8%.
Is Oncopeptides AB's EBITDA Margin % too high?
Oncopeptides AB's current EBITDA Margin % is -147.82%. Based on the distribution chart, Oncopeptides AB ranks #602 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #602 out of 944 companies for EBITDA Margin %. This places Oncopeptides AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current EBITDA Margin % is -147.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.14 — trading 61.6% below its estimated fair value. The current EBITDA Margin % is -147.82%. Oncopeptides AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current EBITDA Margin % is -147.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.14 is trading 61.6% below its estimated GF Value™ of €0.37.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
EBITDA Margin %: -147.82%
GF Value™: €0.37 vs. price of €0.14 (61.6% below fair value)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
30GF Score
Get the complete analysis for FRA:OND
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
